Eniola should open by inverting the typical cold-apply narrative: Servier is not a target she is pitching toward — it is already the named milestone partner in her roadmap, and SPartners is the institutional mechanism to formalise what is currently an arm's-length relationship. She should present her platform's 100% mutation coverage (versus 17.6% for structure-limited tools) and AUROC parity with mCSM-lig as a validated proof-of-concept that is compute-efficient but residency-bounded: the ESM-2 fine-tuning on SKEMPI data and the AUROC ≥ 0.70 milestone require access to Servier's proprietary mutation datasets and medicinal chemistry expertise — exactly what the incubator unlocks. For the Golden Ticket angle, she should explicitly frame the platform as an oncology drug-resistance asset (mutation-driven resistance in targeted therapy is a Servier oncology priority) to qualify under their therapeutic preference criteria.